Etodolac double-layered osmotic pump controlled release tablets, and preparation method thereof

An osmotic pump controlled-release and etodolac technology, applied in the field of medicine, can solve the problems of easy forgetting to take medicine, low blood concentration, and inconvenience for patients, achieve lasting effective blood concentration, reduce the number of administrations, and reduce toxicity. side effects

Inactive Publication Date: 2012-02-01
SHIJIAZHUANG UNIVERSITY
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0007] Ordinary etodolac preparations are administered three times a day, and patients often forget to take the medicine
Taking the medicine three times a day, in principle, it should be administered every 8 hours, but it is very difficult in practice. The interval between taking the medicine three times during the day is relatively short, and the time from taking the medicine at night to the next morning is long, resulting in low blood drug concentration in the morning. The effect of the drug is reduced, and this dosage regimen is very inconvenient for the patient

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Etodolac double-layered osmotic pump controlled release tablets, and preparation method thereof
  • Etodolac double-layered osmotic pump controlled release tablets, and preparation method thereof
  • Etodolac double-layered osmotic pump controlled release tablets, and preparation method thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0033] Party:

[0034] Drug-containing layer (specification 100mg / tablet)

[0035] etodolac 100mg

[0036] PEO (polyoxyethylene) VROH or CMC-Na (sodium carboxymethylcellulose) or HPMC K4M (Hypromellose) or CP 971NF (Carbomer)) 186mg

[0037] Booster layer (mg / tablet)

[0038] CMS-Na56

[0039] HPMC K100M 45

[0040] CP 971NF 11.6

[0041] pvp K30 twenty two

[0042] NaCl 32.5

[0043] Fe 2 o 3 1.55

[0044] Coating prescription (mg)

[0045] CA 15

[0046]PEG 3

[0047] Acetone 1000ml

[0048] In this experiment, PEO VROH (polyoxyethylene), CMC-Na (sodium carboxymethyl cellulose), HPMC K4M (Hydroxypropylmethylcellulose), CP 971NF One of the (carbomer) is used as the drug carrier of the drug-containing layer, and the influence of the polymer carrier on drug release is investigated.

[0049] Preparation method: crush etodolac and drug-containing layer auxiliary materials, pass through a 60-mesh sieve, mix well, add an app...

Embodiment 2

[0054] Party:

[0055] Drug-containing layer (specification 100mg / tablet)

[0056] etodolac 35% 100mg

[0057] PEO VROH 30%; 50%; 65% respectively 86mg; 143mg; 186mg

[0058] Booster layer (mg / tablet)

[0059] CMS-Na56

[0060] HPMC K100M 45

[0061] CP 971NF 11.6

[0062] pvp K30 twenty two

[0063] NaCl 32.5

[0064] Fe 2 o 3 1.55

[0065] Coating prescription (mg)

[0066] CA 15

[0067] PEG 3

[0068] Acetone 1000ml

[0069] The amount of PEO used in this experiment was 30%, 50% and 65%, respectively. The release rate of the controlled-release tablets within 24 hours was measured according to the release rate method, indicating that different amounts of polyoxyethylene had an effect on the cumulative release of the drug within 24 hours.

[0070] Preparation method: crush etodolac and drug-containing layer auxiliary materials, pass through a 60-mesh sieve, mix well, use an appropriate amount of isopropanol to make a sof...

Embodiment 3

[0075] Party:

[0076] Drug-containing layer (specification 100mg / tablet)

[0077] etodolac 100mg

[0078] PEO VROH 186mg

[0079] Booster layer (mg / tablet)

[0080] CMS-Na 46; 56; 66

[0081] HPMC K100M 45

[0082] CP 971NF 11.6

[0083] pvp K30 twenty two

[0084] NaCl 32.5

[0085] Fe 2 o 3 1.55

[0086] Coating prescription (mg)

[0087] CA 15

[0088] PEG 3

[0089] Acetone 1000ml

[0090] Keep other prescriptions of the booster layer unchanged, change the dosage of CMS-Na to 46mg, 56mg, 66mg, measure the release rate of the controlled-release tablet within 24h according to the release rate measurement method, and investigate its influence on the release rate.

[0091] Preparation method: crush etodolac and drug-containing layer auxiliary materials, pass through a 60-mesh sieve, mix well, use an appropriate amount of isopropanol to make a soft material, granulate with a 16-mesh sieve, dry at 40°C, and g...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
hardnessaaaaaaaaaa
Login to view more

Abstract

The invention belongs to the field of medicines, and specifically discloses etodolac double-layered osmotic pump controlled release tablets, and a preparation method thereof. The etodolac double-layered osmotic pump controlled release tablets provided by the invention are double-layered tablets with semi permeable membranes. The upper layers of the tablets are medicine-containing layers comprising medicines and auxiliary materials, and the lower layers are assisting layers composed of polymers and osmotically active substances. The etodolac double-layered osmotic pump controlled release tablets provided by the invention have advantages of stable in vivo blood-drug level, and long effective blood-drug level duration.

Description

technical field [0001] The invention belongs to the field of medicine, and more specifically, the invention discloses an osmotic pump controlled-release tablet and a preparation method thereof. Background technique [0002] Etodolac is a pyranose carboxylic acid non-steroidal anti-inflammatory drug developed by France in the mid-1970s. It has analgesic and anti-inflammatory properties. It can reduce the level of uric acid in human blood to treat gout (USA Patent 4,633,354), and treat rheumatoid arthritis by reducing rheumatoid factor in blood (US Patent 4,742,076), which is a new generation of cyclooxygenase highly selective anti-inflammatory drugs. Its anti-inflammatory and analgesic effect is exact, high in safety, gastrointestinal adverse reactions and renal function damage rarely occur, and it is widely used clinically to treat postoperative pain, relieve symptoms of rheumatoid arthritis, osteoarthritis and arthritis The bone pathological changes caused by it are recomm...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K9/24A61K31/407A61K47/38A61K47/34A61K47/36A61K47/32A61P29/00A61P19/06A61P19/02A61P19/04
Inventor 岳红坤常明王景翔牟微张东红
Owner SHIJIAZHUANG UNIVERSITY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap